Precision medicine targets a limited pool of biomarker-positive patients. Knowing if your target market tests for your biomarker of interest is critical for accurate commercial forecasts, efficient investments, and successful uptake of your precision therapies. Tap into SOPHiA DDM™ to quickly access a vast clinical research network and stay up to date with the rapidly-changing genetic testing landscape.

**Market Access**
Determine the need to integrate **companion diagnostics** in your roadmap and operational plan by understanding the real-world genetic testing landscape in your target market.

**Supply Chain Management**
Determine the geographical distribution of **biomarker-positive populations** to deliver your precision therapeutics to the right target.

**Medical Education Strategy**
Understand the **gaps in care, knowledge, and capacity** in your target market to build more engaging medical education strategies and promote precision medicine adoption.

**Benefits of SOPHiA DDM™ Awareness**
- Generate **accurate and data-first commercial forecasts** in less time by accessing Real-World Clinical Data
- Improve your **go-to-market strategy** by understanding your customers’ pain points and needs
- Spend **less time** developing your clinical network and instantly tap into an established network of over 750 institutions worldwide

---

Optimize access to market with SOPHiA DDM™ Awareness

Identify the genomic biomarker of interest

Run a prospective query on SOPHiA DDM™

Define the geographic scope of interest

Get frequent aggregated statistical data insights reports

CASE STUDY
SOPHiA DDM™ Awareness Identifies Cluster of Patients with RET Alterations

RET gene alterations are rare (present in only 1-2% of NSCLC patients) but critical drivers of growth and proliferation in diverse solid tumors. It is vital to cast light on current practices and to raise awareness about the importance of routine RET testing.

Key insights
1. In France, 2% of cancer patients tested with NGS panels targeting RET alterations carried an oncogenic mutation or fusion.
2. According to the literature, all RET fusions identified in the population are associated with lung cancer.
3. Awareness reports helped pinpoint regions where patients could benefit the most from precision therapies targeting RET alterations.

About SOPHiA GENETICS

750+ Healthcare Institutions

70+ Countries

1 Million+ Genomic Profiles

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ platform and related solutions, products and services were used by more than 750 hospitals, laboratories, and biopharma institutions globally in 2021.

Want to learn more?

Or contact us at:
info@sophiagenetics.com

The information included in this flyer has been prepared for and is intended for viewing by a global audience. This flyer contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please consult local sales representatives. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. SOPHiA DDM™ Awareness is for Research Use Only and is not intended for purposes other than research. SOPHiA DDM™ is not for diagnostic, therapeutic, or treatment purposes.

© SOPHiA GENETICS 2022. GL-BP-2200015-r1